F
Faiza Khemissa-Akouz
Publications - 5
Citations - 7667
Faiza Khemissa-Akouz is an academic researcher. The author has contributed to research in topics: FOLFIRINOX & Gemcitabine. The author has an hindex of 5, co-authored 5 publications receiving 5893 citations.
Papers
More filters
Journal ArticleDOI
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy,Françoise Desseigne,Marc Ychou,Olivier Bouché,Rosine Guimbaud,Yves Becouarn,Antoine Adenis,Jean-Luc Raoul,Sophie Gourgou-Bourgade,Jaafar Bennouna,Jean-Baptiste Bachet,Faiza Khemissa-Akouz,Denis Péré-Vergé,Catherine Delbaldo,Eric Assenat,Bruno Chauffert,C. Montoto-Grillot,Michel Ducreux +17 more
TL;DR: FOLFIRINOX was associated with a survival advantage and had increased toxicity as compared with gemcitabine, and is an option for the treatment of patients with metastatic pancreatic cancer and good performance status.
Journal ArticleDOI
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Thierry Conroy,Pascal Hammel,Mohamed Hebbar,Meher Ben Abdelghani,Alice C. Wei,Jean-Luc Raoul,Laurence Chone,Eric Francois,Pascal Artru,James Joseph Biagi,Thierry Lecomte,Eric Assenat,Roger Faroux,Marc Ychou,Julien Volet,Alain Sauvanet,Gilles Breysacher,Frédéric Di Fiore,Christine Cripps,Petr Kavan,Patrick Texereau,Karine Bouhier-Leporrier,Faiza Khemissa-Akouz,Jean-Louis Legoux,Beata Juzyna,Sophie Gourgou,Christopher J. O'Callaghan,Claire Jouffroy-Zeller,Patrick Rat,David Malka,Florence Castan,Jean-Baptiste Bachet +31 more
TL;DR: Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects.
Journal ArticleDOI
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Anthony Dohan,Benoit Gallix,Boris Guiu,Karine Le Malicot,Caroline Reinhold,Philippe Soyer,Jaafar Bennouna,François Ghiringhelli,Emilie Barbier,Valérie Boige,Julien Taieb,Olivier Bouché,Eric Francois,Jean-Marc Phelip,Christian Borel,Roger Faroux,Jean-François Seitz,Stephane Jacquot,Meher Ben Abdelghani,Faiza Khemissa-Akouz,Dominique Genet,Jean Louis Jouve,Yves Rinaldi,Françoise Desseigne,Patrick Texereau,Etienne Suc,Côme Lepage,Thomas Aparicio,Christine Hoeffel +28 more
TL;DR: A radiomic signature was able to predict OS, and identify good responders better than RECIST1.1 criteria in patients with mCRC treated by FOLFIRI and bevacizumab as a first-line treatment.
Journal ArticleDOI
Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial
François-Clément Bidard,François-Clément Bidard,François-Clément Bidard,Nicolas Kiavue,Marc Ychou,Luc Cabel,Luc Cabel,Luc Cabel,Marc-Henri Stern,Jordan Madic,Adrien Saliou,Aurore Rampanou,Charles Decraene,Olivier Bouché,Michel Rivoire,François Ghiringhelli,Eric Francois,Rosine Guimbaud,Laurent Mineur,Faiza Khemissa-Akouz,Thibault Mazard,Driffa Moussata,Charlotte Proudhon,Jean-Yves Pierga,Jean-Yves Pierga,Trevor Stanbury,Simon Thezenas,Pascale Mariani +27 more
TL;DR: In CRC patients with limited metastatic spread, ctDNA could be used as liquid biopsy tool and could help to select patients eligible for LM resection, according to the clinical validity of circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) detection.
Journal Article
[A comparison of serum Cyfra 21-1 and SCC AG in the diagnosis of squamous cell esophageal carcinoma].
TL;DR: The value of Cyfra 21-1 in OSCC at the normal level of 1.5 ng/ml is confirmed and the combination with SC improves the results.